Bayer doubles down on Factor XIa with new phase 3 trial

cafead

Administrator
Staff member
  • cafead   Nov 06, 2023 at 10:12: AM
via Bayer has added another phase 3 trial into its registration program for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

article source
 

<